June 29, 2022

HowardNema.com

BUILD BACK BETTER MEANS SLAVERY & GENOCIDE! NON-COMPLIANCE IS OUR ONLY HOPE! THE UN/DAVOS ELITE HAVE LAUNCHED A QUIET WAR AGAINST HUMANITY FOUGHT WITH SILENT WEAPONS OF MASS DECEPTION AND MASS DESTRUCTION! SAVE HUMANITY! DOWNLOAD AND SHARE ALL THE LINKS, BOOKS, VIDEOS, INTERVIEWS, STUDIES, WHITE PAPERS, ARTICLES AND DOCUMENTARIES AVAILABLE ON THIS SITE THAT EXPOSES THIS EVIL AGENDA! TELL OTHERS TO DO THE SAME! WE MUST GET THIS HEAVILY CENSORED INFORMATION OUT TO THE PUBLIC!

OPPOSE THE FRAUD – JAMES ROGUSKI

by James Roguski

The FDA has scheduled meetings to consider authorizing the use of Pfizer and Moderna injections in children and infants as young as 6 months. THIS MUST BE STOPPED.

Scroll down the page in order to send emails, make phone calls, submit comments and help spread the word.

PLEASE SHARE THIS LINK WITH EVERYONE YOU KNOW ASAP:

http://OpposeTheFraud.com

https://www.youtube-nocookie.com/embed/7xFuk8bmzm0?rel=0&autoplay=0&showinfo=0&enablejsapi=0

Share

CLICK ON ALL OF THE OPTIONS BELOW TO SEND A MULTITUDE OF EMAILS:

CLICK TO SUBMIT COMMENT BY JUNE 13, 2022: https://www.federalregister.gov/documents/2022/05/31/2022-11669/vaccines-and-related-biological-products-advisory-committee-notice-of-meeting-establishment-of-a#open-comment

NOTE: When you click on the image above, sometimes a popup appears that seems to state that the comment submission form is not available. IGNORE the popup. Just close the popup and submit your comment. It seems to be just another mental hurdle to avoid.

IGNORE THIS POPUP IF YOU SEE IT

NOTE 2: The form has a drop down menu that appears to be blank on some browsers. For most people, the most appropriate choice seems to be “individual consumer,” but you should choose whichever option seems best for you.

ORAL PRESENTATIONS:

Those individuals interested in making formal oral presentations should notify the contact person and submit a brief statement of the general nature of the evidence or arguments they wish to present, the names and email addresses of proposed participants, and an indication of the approximate time requested to make their presentation on or before 6 p.m. ET on June 8, 2022.

CONTACT:  Prabhakara Atreya or  Sussan Paydar, Center for Biologics Evaluation and Research, Food and Drug Administration, 10903 New Hampshire Ave., Bldg. 71, Silver Spring, MD 20993-0002, 240-506-4946, or via email at CBERVRBPAC@fda.hhs.gov; or FDA Advisory Committee Information Line, 1-800-741-8138 (301-443-0572 in the Washington, DC area). 

Oral presentations from the public will be scheduled between approximately 1:00 p.m. and 2:00 p.m. ET.  Time allotted for each presentation may be limited.

If the number of registrants requesting to speak is greater than can be reasonably accommodated during the scheduled open public hearing session, FDA may conduct a lottery to determine the speakers for the scheduled open public hearing session.

The contact person will notify interested persons regarding their request to speak by June 10, 2022.

Share

TAKE ACTION

Click on each of the images below and take as many of the following actions as you possibly can !

Contact the people listed below and share your personalized opinion with them A.S.A.P. Please feel free to use your own words. The text below are merely a suggested starting point.


SAMPLE EMAIL:

Follow the Science, Children DO NOT need the COVID vaccine!

The U.S. Food and Drug Administration’s (FDA) Vaccines and Related Biological Products Advisory Committee is considering Pfizer’s application for Emergency Use Authorization (EUA) status for its COVID vaccine to be used in the 6 months to 5 years old.

The meeting in February was postponed due to the lack of available safety and efficacy data.

Babies and young children aren’t at risk of serious complications or death from COVID. However, they are at risk from injury and even death from COVID vaccines.

I am writing to you today to call your attention to the latest data from the Vaccine Adverse Events Reporting System which should give anyone pause when considering this particular vaccine for such a vulnerable population. Between mid-December, 2020 through March 18, 2022, there have been 1,195,936 adverse events following COVID vaccination including 26,059 deaths.

Abundant evidence shows that COVID poses nearly zero risk to this age group:

  1. A Johns Hopkins study monitoring 48,000 children diagnosed with COVID showed a zero mortality rate in children under 18 without comorbidities.
  2. A study in Nature demonstrated that children under 18 with no comorbidities have virtually no risk of death.
  3. Data from England and Wales, published by the UK Office of National Statistics on January 17, 2022, revealed that throughout 2020 and 2021, only one child under the age of 5, without comorbidities, died from COVID in the two countries, whose total population is 60 million.
  4. A large study conducted in Germany showed zero deaths for children 5-11 and a case fatality rate of three out of a million in children without comorbidities.
  5. Another study in Nature from April 2021, suggests children’s bodies clear the virus more easily than adults.
  6. A study published in December in Nature demonstrated how children efficiently mount effective, robust and sustained immune responses to COVID.

To even consider further exposure to this very risky vaccine among the infants and young children of this nation is unconscionable. I urge you to do everything in your power to halt any further discussion of granting EUA status to this age group.

Please be advised that your actions during the upcoming VRBPAC meetings will be viewed by millions of Americans and millions of additional concerned people around the world.

WE ARE ALL VERY MUCH AWARE that the risk of serious disease or death due to COVID-19 is practically ZERO in children from 6 months to 6 years of age (and up).

There can be no valid risk/benefit analysis because COVID-19 POSES NO RISK TO CHILDREN in the targeted age groups. To vote in favor of authorizing the use of these products when they can only cause harm would be a blatantly criminal act on your part.

There is absolutely NO VALID REASON to approve either the Pfizer-BioNTech or Moderna injections for use in infants and children from 6 months to 5-6 years of age.

YOU KNOW THIS, AND WE KNOW THAT YOU KNOW THIS.

If you vote to authorize for emergency use either the Pfizer-BioNTech or Moderna injections for use during the upcoming meetings on June 14-15, 2022, YOU WILL BE HELD PERSONALLY RESPONSIBLE FOR HEINOUS CRIMES AGAINST HUMANITY.

DON’T YOU DARE VOTE TO APPROVE THESE INJECTIONS!


EMAILS:

Xavier.Becerra@HHS.gov

CBERVRBPAC@fda.hhs.gov

fdaoma@fda.hhs.gov

hagans@stanford.edu

adam.berger@nih.gov

Archana.Chatterjee@RosalindFranklin.edu

acohn@cdc.gov

hjanes@fredhutch.org

david.kim@hhs.gov

jportnoy@cmh.edu

gcsylvester@gmail.com

acip@cdc.gov

Janet.Woodcock@fda.hhs.gov

Peter.Marks@fda.hhs.gov

hanae@bcm.edu

asmonto@umich.edu

archana.chatterjee@rosalindfranklin.edu

acohn@cdc.gov

spergam@fredhutch.org

mlevine@som.umaryland.edu

paul.spearman@cchmc.org

offit@chop.edu

OFFIT@email.chop.edu

swamy002@mc.duke.edu

ashane@emory.edu

hagans@stanford.edu

cmeissner@tuftsmedicalcenter.org

hbernstein@northwell.edu

Jportnoy@cmh.edu

erubin@hsph.harvard.edu

TWITTER:


MAKE SOME PHONE CALLS

PUBLICLY AVAILABLE CONTACT INFO (PHONE NUMBERS):

All of the contact information below is readily available at the link below…

https://www.fda.gov/advisory-committees/vaccines-and-related-biological-products-advisory-committee/roster-vaccines-and-related-biological-products-advisory-committee

Hayley Gans, M.D. Department of Pediatrics, Division of Pediatric Infectious Diseases Stanford University Medical Center, Stanford, CA 94305-5208 Fax: (650) 725-8040 Email: hagans@stanford.edu PHONE: (650) 723-5682

Adam C.Berger, PhD 6705 Rockledge Drive, Suite 630 Bethesda, MD 20892 EMAIL: adam.berger@nih.gov PHONE: 301-827-9676

Archana Chatterjee, M.D., Ph.D. Dean Chicago Medical School  3333 Green Bay Road North Chicago, IL 60064 FAX: 847-578-3345 Email: Archana.Chatterjee@RosalindFranklin.edu PHONE: 847-578-3301

CAPT Amanda Cohn National Center for Immunization and Respiratory Diseases  Centers for Disease Control and Prevention 1600 Clifton Rd, Atlanta, GA 30333 MS C-09 E-mail: acohn@cdc.gov PHONE: (404) 639-6039 

Holly Janes, Ph.D. Fred Hutchinson Cancer Research Center Vaccine and Infectious Disease Division  1100 Fairview Avenue North, M2-C200  P.O. Box 19024 Seattle, Washington 98109  E-mail: hjanes@fredhutch.org PHONE: 206-6676353

David Kim, MD CAPT, U.S. Public Health Service Vaccine Program Office of Infectious Disease and HIV/AIDS Policy Office of the Assistant Secretary for Health U.S. Department of Health and Human Services 330 C Street SW, Suite L600 Washington, DC 20024 Email david.kim@hhs.gov Main (202) 795-7697 PHONE (202) 795-7636

Jay M. Portnoy, MD  Director, Division of Allergy, Asthma & Immunology  Children’s Mercy Hospitals & Clinics  2401 Gillham Road  Kansas City, MO 64108 EMAIL: jportnoy@cmh.edu FAX: (816) 960-8888 PHONE: (816) 960-8885

Andrea (Andi) L. Shane, MD MPH MSc Emory University School of Medicine  2015 Uppergate Drive NE, Rm. 504A Atlanta, GA 30322 EMAIL: ashane@emory.edu FAX: 404-727-8249 MAIN: 404-727-5642 PHONE: 404-727-9880

Gregg C. Sylvester, MD, MPH Head of Medical Affairs for Seqirus 470 Burnt Mill Road  Wilmington, DE 19807  EMAIL: gcsylvester@gmail.com MOBILE: 302-272-0653

I have been unable to find contact information for the following VRBPAC members. Your help will be much appreciated. Post publicly available contact information ONLY in the comment section.

Paula Annunziato, M.D. ***

Henry H. Bernstein, D.O., MHCM, FAAP

Arnold Monto, M.D.

Paul Offit, M.D.

Steven Pergam, M.D.

Eric J. Rubin, M.D., Ph.D.

Geeta K. Swamy, M.D.


FDA Contact Information:

  • Prabhakara Atreya: 240-506-4946
  • Sussan Paydar: CBERVRBPAC@fda.hhs.gov
  • FDA Advisory Committee Information Line:
    1-800-741-8138 or 301-443-0572
  • For press inquiries, please contact the Office of Media Affairs at fdaoma@fda.hhs.gov or 301-796-4540

Please watch these videos and take the appropriate actions…

https://rumble.com/v17gfdn-june-fda-meetings.html



https://www.rokfin.com/post/88804/FDA-Fast-Tracking-Novavax-For-Kids-And-Babies


Enough is Enough – Doctors Send Warning to Parents as FDA nears EUA of COVID Shots for Under 5

https://live.childrenshealthdefense.org/shows/chd-friday-roundtable/78vSrHX82_


SCROLL DOWN TO WATCH LIVESTREAMS OR RECORDINGS OF FDA AND CDC MEETINGS

June 7, 2022 – VRBPAC meeting regarding Novavax

June 7, 2022 – Deadline for written comments to be made available to Committee that is meeting on June 14-15. (SUBMIT WRITTEN COMMENT HERE)

June 8, 2022 – Deadline to send email request to make oral comments during June 14-15 meeting (see details below)

June 13, 2022 – Deadline for comments to be considered by the FDA. (SUBMIT WRITTEN COMMENT HERE)

June 14, 2022 – VRBPAC meeting regarding Moderna (6-17 year olds)

June 15, 2022 – Pfizer-BioNTech and Moderna in babies

June 15, 2022 – Deadline for submitting request to provide oral public comment during June 17-18 ACIP meeting. (SUBMIT REQUEST FOR ORAL PUBLIC COMMENT HERE)

June 17-18, 2022 – ACIP meeting

June 22, 2022 – Deadline for written comments to be made available to Committee that is meeting on June 28, 2022

June 22-23, 2022 – ACIP meeting

June 27, 2022 – Deadline for comments to be considered by the FDA regarding the June 28 meeting.

June 28, 2022 – Bypassing studies for future injections

It appears that the FDA and the CDC are not even pretending to care about science anymore.

The FDA’s Vaccines and Related Biological Products Advisory Committee (VRBPAC) wants to grant Emergency Use Authorization to Pfizer’s BioNTech and Moderna’s injectable bioweapons for babies aged 6 months and children up to 5 years old, despite the lack of evidence of safety and efficacy to support its use.

This may be yet another Fantastically Dumb Action by the FDA.

“If your blood is not boiling, it must be clotting.”

-Rajen M.

PFIZER:

  1. The Pfizer clinical trial in kids under 5 failed in December 2021.
  2. Pfizer added a third dose and that trial also failed in February, which is why they withdrew their application on February 10, 2022.
  3. Now Pfizer is describing a jerry-rigged trial of a third dose in 1,678 kids ages 6 months to four years old.
  4. Pfizer has not disclosed how the kids were divided between the treatment and control group so it is impossible determine efficacy.
  5. Out of that sample, 10 developed COVID-19 — although it is not clear how the 10 were distributed between the treatment and control group.
  6. Pfizer is NOT looking at health outcomes in the real world (because there are none). Instead, all of their claims are based on measurements of antibodies in the blood.
  7. The FDA’s Vaccines and Related Biological Products Advisory Committee unanimously acknowledged on April 6 that proxy measurements, such as antibody counts, DO NOT determine whether someone is immune to the virus or not.
  8. The only reason Pfizer and the FDA are focused on antibodies in the blood is because the trial produced NO clinically significant health outcomes.
  9. Pfizer also failed to describe the contents of the “placebo.”
  10. The US Food and Drug Administration has clearly added a warning about the additional risks of myocarditis and pericarditis connected to the Pfizer-BioNTech Covid-19 injections.

MODERNA:

  1. Moderna’s injections have been reported to be 37-51% effective.
  2. Moderna’s injections have NOT been approved in those who are under 18 years of age.
  3. Moderna is NOT looking at health outcomes in the real world (because there are none). Instead, all of their claims are based on measurements of antibodies in the blood.
  4. The FDA’s Vaccines and Related Biological Products Advisory Committee unanimously acknowledged on April 6 that proxy measurements, such as antibody counts, DO NOT determine whether someone is immune to the virus or not.
  5. The US Food and Drug Administration has clearly added a warning about the additional risks of myocarditis and pericarditis connected to the Moderna Covid-19 injections.

The White House has just announced that they have purchased 10 million doses of Pfizer and Moderna COVID-19 mRNA vaccines that became available today for all 50 states to purchase in preparation for injecting babies and toddlers between the ages of 6 months and 5 years old within the next few weeks.

And since the FDA has not even conducted an advisory committee meeting yet, let alone issued emergency use authorizations for this age group, the purchase and distribution of these killer shots proves once again that the FDA just rubber stamps whatever the pharmaceutical industry wants.

https://vaccineimpact.com/2022/infanticide-10-million-babies-and-toddlers-targeted-for-slaughter-by-biden-administration-with-pfizer-and-moderna-mrna-injections/

FDA MEETING 1

WATCH THE MEETING ON TUESDAY JUNE 7, 2022:

The committee will meet in open session to discuss an Emergency Use Authorization (EUA) request by Novavax for a vaccine to prevent COVID-19 in individuals 18 years of age and older.

CLICK HERE TO REVIEW THE DOCUMENTS

ANNOUNCEMENT PAGE:

https://www.fda.gov/advisory-committees/advisory-committee-calendar/vaccines-and-related-biological-products-advisory-committee-june-7-2022-meeting-announcement

https://www.youtube-nocookie.com/embed/DfdMsAqkneE?rel=0&autoplay=0&showinfo=0&enablejsapi=0

Contact Information:

  • Prabhakara Atreya (240-506-4946) or Sussan Paydar: CBERVRBPAC@fda.hhs.gov
  • FDA Advisory Committee Information Line:
    1-800-741-8138 (301-443-0572 in the Washington, DC area) Please call the Information Line for up-to-date information on this meeting.
  • For press inquiries, please contact the Office of Media Affairs at fdaoma@fda.hhs.gov or 301-796-4540.

FDA MEETING 2

WATCH THE MEETING ON TUESDAY JUNE 14, 2022:

The Docket Number is FDA-2022-N-0904

On June 14, 2022, under Topic 1, the committee will meet in open session to discuss amending the EUA of the Moderna COVID-19 mRNA vaccine to include the administration of the primary series to children and adolescents 6 years through 17 years of age.

DOCUMENTS ARE NOT YET AVAILABLE

FEDERAL REGISTER:

https://www.federalregister.gov/documents/2022/05/31/2022-11669/vaccines-and-related-biological-products-advisory-committee-notice-of-meeting-establishment-of-a

SUBMIT A PUBLIC COMMENT:

https://www.federalregister.gov/documents/2022/05/31/2022-11669/vaccines-and-related-biological-products-advisory-committee-notice-of-meeting-establishment-of-a#open-comment

ANNOUNCEMENT:

https://www.fda.gov/advisory-committees/advisory-committee-calendar/vaccines-and-related-biological-products-advisory-committee-june-14-15-2022-meeting-announcement

https://www.youtube-nocookie.com/embed/GbNpaZeDPiA?rel=0&autoplay=0&showinfo=0&enablejsapi=0

FOR FURTHER INFORMATION CONTACT:  Prabhakara Atreya or  Sussan Paydar, Center for Biologics Evaluation and Research, Food and Drug Administration, 10903 New Hampshire Ave., Bldg. 71, Silver Spring, MD 20993-0002, 240-506-4946, or via email at CBERVRBPAC@fda.hhs.gov; or FDA Advisory Committee Information Line, 1-800-741-8138 (301-443-0572 in the Washington, DC area). 

For press inquiries, please contact the Office of Media Affairs at fdaoma@fda.hhs.gov or 301-796-4540.

Share

FDA MEETING 3

WATCH THE MEETING ON WEDNESDAY JUNE 15, 2022:

The Docket Number is FDA-2022-N-0904

On June 15, 2022, under Topic II, the committee will meet in open session to discuss

  1. amending the EUA of the Moderna COVID-19 mRNA vaccine to include the administration of the primary series to infants and children 6 months through 5 years of age
  2. amending the EUA of the Pfizer-BioNTech COVID-19 mRNA vaccine to include the administration of the primary series to infants and children 6 months through 4 years of age.

ANNOUNCEMENT PAGE:

https://www.fda.gov/advisory-committees/advisory-committee-calendar/vaccines-and-related-biological-products-advisory-committee-june-14-15-2022-meeting-announcement

INFORMATIONAL DOCUMENTS ARE NOT YET AVAILABLE

SUBMIT A WRITTEN PUBLIC COMMENT:

https://www.federalregister.gov/documents/2022/05/31/2022-11669/vaccines-and-related-biological-products-advisory-committee-notice-of-meeting-establishment-of-a#open-comment

Comments received on or before June 7, 2022, will be provided to the committee. Comments received after June 7, 2022, and by June 13, 2022, will be taken into consideration by FDA.

ORAL PRESENTATIONS:

Those individuals interested in making formal oral presentations should notify the contact person and submit a brief statement of the general nature of the evidence or arguments they wish to present, the names and email addresses of proposed participants, and an indication of the approximate time requested to make their presentation on or before 6 p.m. ET on June 8, 2022.

CONTACT:  Prabhakara Atreya or  Sussan Paydar, Center for Biologics Evaluation and Research, Food and Drug Administration, 10903 New Hampshire Ave., Bldg. 71, Silver Spring, MD 20993-0002, 240-506-4946, or via email at CBERVRBPAC@fda.hhs.gov; or FDA Advisory Committee Information Line, 1-800-741-8138 (301-443-0572 in the Washington, DC area). 

Oral presentations from the public will be scheduled between approximately 1:00 p.m. and 2:00 p.m. ET.  Time allotted for each presentation may be limited.

If the number of registrants requesting to speak is greater than can be reasonably accommodated during the scheduled open public hearing session, FDA may conduct a lottery to determine the speakers for the scheduled open public hearing session.

The contact person will notify interested persons regarding their request to speak by June 10, 2022.

FEDERAL REGISTER:

https://www.federalregister.gov/documents/2022/05/31/2022-11669/vaccines-and-related-biological-products-advisory-committee-notice-of-meeting-establishment-of-a

The FDA intends to make background material available to the public no later than 2 business days before the meeting.  If FDA is unable to post the background material on its website prior to the meeting, any background material will be made publicly available at the time of the advisory committee meeting, and additional materials will be posted on FDA’s website after the meeting.

https://www.youtube-nocookie.com/embed/Ixm4UmldTGQ?rel=0&autoplay=0&showinfo=0&enablejsapi=0

FOR FURTHER INFORMATION CONTACT:  Prabhakara Atreya or  Sussan Paydar, Center for Biologics Evaluation and Research, Food and Drug Administration, 10903 New Hampshire Ave., Bldg. 71, Silver Spring, MD 20993-0002, 240-506-4946, or via email at CBERVRBPAC@fda.hhs.gov; or FDA Advisory Committee Information Line, 1-800-741-8138 (301-443-0572 in the Washington, DC area). 

For press inquiries, please contact the Office of Media Affairs at fdaoma@fda.hhs.gov or 301-796-4540.

Share

CDC MEETING 1

June 17, 2022:  10:00am – 3:30pm ET

June 18, 2022:  10:00am – 4:00pm ET

How to Submit a Written Public Comment

Any member of the public can submit a written public comment to ACIP. Written comments must be received by June 18, 2022, identified by Docket No. TBA using the Federal eRulemaking Portal. Follow the instructions for submitting comments. All submissions received must include the agency name and Docket Number.

All relevant comments received will be posted without change to

http://regulations.gov

, including any personal information provided. For access to the docket or to read background documents or comments received, go to

http://www.regulations.gov

How to Request to Make an Oral Public Comment

The June 17-18, 2022 ACIP meeting will be a virtual meeting and will include time for oral public comment for members of the public. All individuals interested in making an oral public comment are strongly encouraged to submit a request no later than 11:59 p.m., EST, June 15, 2022 as there will be no opportunity to register for oral public comment later than June 15th .

If the number of persons requesting to speak is greater than can be reasonably accommodated during the scheduled time, CDC will conduct a lottery to determine the speakers for the scheduled public comment session. CDC staff will notify individuals regarding their request to speak by email June 16, 2022. To accommodate the significant interest in participation in the oral public comment session of ACIP meetings, each speaker will be limited to 3 minutes, and each speaker may only speak once per meeting.

Request to Make an Oral Public Comment

The June 17-18, 2022 ACIP meeting will be a virtual meeting and will include time for oral public comment for members of the public.

If the number of people requesting to speak is greater than can be reasonably accommodated during the time scheduled for oral public comment, CDC may conduct a lottery to determine the speakers. CDC staff will notify individuals regarding their request to speak via email by June 16, 2022.

To accommodate the significant interest in participation in the oral public comment session of ACIP meetings, each speaker will be limited to 3 minutes, and each speaker may only speak once per meeting. Interested persons who are unable to make an oral public comment during this meeting are invited to submit a written comment.

Requests to Make an Oral Public Comment is Open

Oral Public Comment for June 17-18, 2022 Meeting

Register Now

https://www2.cdc.gov/vaccines/acip/acip_publiccomment.asp

WATCH THE LIVESTREAM:

https://video.ibm.com/channel/VWBXKBR8af4


https://www.cdc.gov/vaccines/acip/members/bios.html

CDC MEETING 2

June 22, 2022:  10:00am – 5:00pm ET

June 23, 2022:  10:00am – 2:00pm ET

FEDERAL REGISTER:

https://www.federalregister.gov/documents/2022/05/10/2022-09950/advisory-committee-on-immunization-practices-acip

Matters to be considered: The agenda will include discussions on influenza vaccines; pneumococcal vaccine; human papillomavirus vaccine; measles, mumps, rubella (MMR) vaccine; respiratory syncytial virus vaccine; rotavirus vaccine; and Chikungunya vaccine. Recommendation votes on influenza vaccines, pneumococcal vaccine, and MMR vaccine are scheduled. No VFC votes are scheduled. Agenda items are subject to change as priorities dictate.

Written comments must be received on or before June 23, 2022.

Written Public Comment: The docket will be opened to receive written comments on May 10, 2022. Written comments must be received on or before June 23, 2022.

Oral Public Comment: This meeting will include time for members of the public to make an oral comment. Oral public comment will occur before any scheduled votes, including all votes relevant to the ACIP’s Affordable Care Act and Vaccines for Children program roles. Priority will be given to individuals who submit a request to make an oral public comment before the meeting according to the procedures below.

Procedure for Oral Public Comment: All persons interested in making an oral public comment at the June 22-23, 2022, ACIP meeting must submit a request at https://www.cdc.gov/​vaccines/​acip/​meetings/​index.html no later than 11:59 p.m., EDT, June 13, 2022, according to the instructions provided.

FDA MEETING 4

WATCH THE MEETING ON TUESDAY JUNE 28, 2022:

The Docket Number is FDA-2022-N-0905

COMMENT: https://www.regulations.gov/commenton/FDA-2022-N-0905-0001

The committee will meet in open session to discuss whether and how the SARS-CoV-2 strain composition of COVID-19 vaccines should be modified.

The purpose of the “Future Framework” is to rig the Covid-19 vaccine regulatory process in perpetuity in favor of the pharmaceutical industry. If this “Future Framework” is approved all future Covid-19 shots, regardless of the formulation, will automatically be deemed “safe and effective” without additional clinical trials because they are considered “biologically similar” to existing shots.

This is literally the worst idea in the history of public health.

If you change a single molecule of mRNA in these shots it will change health outcomes in ways that no one can anticipate. That necessarily requires new clinical trials — which is what the FDA is proposing to skip.

-Toby Rogers (see article below)

SUBMIT A PUBLIC COMMENT:

https://www.federalregister.gov/documents/2022/05/31/2022-11670/vaccines-and-related-biological-products-advisory-committee-notice-of-meeting-establishment-of-a#open-comment

FEDERAL REGISTER:

https://www.federalregister.gov/documents/2022/05/31/2022-11670/vaccines-and-related-biological-products-advisory-committee-notice-of-meeting-establishment-of-a#open-comment

ANNOUNCEMENT PAGE:

https://www.fda.gov/advisory-committees/advisory-committee-calendar/vaccines-and-related-biological-products-advisory-committee-june-28-2022-meeting-announcement

https://www.youtube-nocookie.com/embed/BFdzNUus_CE?rel=0&autoplay=0&showinfo=0&enablejsapi=0

PROCEDURE: On June 28, 2022, from 8:30 a.m. to 5 p.m. ET, the meeting is open to the public.  Interested persons may present data, information, or views, orally or in writing, on issues pending before the committee.  All electronic and written submissions submitted to the Docket (see ADDRESSES) on or before June 22, 2022, will be provided to the committee.  Comments received after June 22, 2022, and by June 27, 2022, will be taken into consideration by FDA.

ORAL PRESENTATIONS: Oral presentations from the public will be scheduled between approximately 1:30 p.m. and 2:30 p.m. ET.  Those individuals interested in making formal oral presentations should notify the contact person and submit a brief statement of the general nature of the evidence or arguments they wish to present, the names and email addresses of proposed participants, and an indication of the approximate time requested to make their presentation on or before 6 p.m. ET on June 21, 2022.  Time allotted for each presentation may be limited.  If the number of registrants requesting to speak is greater than can be reasonably accommodated during the scheduled open public hearing session, FDA may conduct a lottery to determine the speakers for the scheduled open public hearing session.  The contact person will notify interested persons regarding their request to speak by June 23, 2022.

For press inquiries, please contact the Office of Media Affairs at fdaoma@fda.hhs.gov or 301-796-4540.

error

Share the truth!

Follow by Email
RSS